The Business Research Company's X-linked Hypophosphatemia Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest Report Explores ...

Injectafer isn’t likely to cause any long-term side effects. However, some people may experience severe hypophosphatemia. Very rarely, Injectafer may also cause long-lasting skin discoloration ...

Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment ...

Shift of phosphorus from extracellular to intracellular compartments, decreased gastrointestinal absorption, and increased urinary losses, are the primary mechanisms of hypophosphatemia ...

XLH (“X” denotes X-chromosome, a sex-determining chromosome) is a rare bone disease characterised by hypophosphatemia (i.e., low phosphate in blood). It is caused by a mutation in the phosphate ...

XLH ("X" denotes X-chromosome, a sex-determining chromosome) is a rare bone disease characterised by hypophosphatemia (i.e., low phosphate in blood). It is caused by a mutation in the phosphate ...

in adults with X-linked hypophosphatemia (XLH) following treatment with burosumab (CRYSVITA) in real-world clinical practice. These results were shared with attendees at the American Society for Bone ...

The oral presentation of "Patient reported outcomes (PRO) from a real-world study of burosumab treatment in adults with X-linked hypophosphatemia in the UK" will be made by Judith Bubbear ...

Some people are more at risk for developing low phosphorus levels, known as hypophosphatemia in the medical field. Hypophosphatemia is when blood levels of phosphorus fall below 2.5 milligrams per ...